Celltrion and CSL signed an agreement for the development and supply of CSL 360, a mAb for the treatment of acute myeloid leukemia. CSL is currently conducting Phase I trials for the candidate in Australia.

Celltrion will provide process development expertise and supply clinical and commercial material to support the clinical the ongoing development program and the possible future commercialization of the product. The firms say that there is potential for a longer term strategic manufacturing relationship as well.

Next articleUMMZ Periodical Cicada Page